Drug Profile
AC 076
Alternative Names: AC-076A; AC-76; AC076Latest Information Update: 28 Nov 2019
Price :
$50
*
At a glance
- Originator Actelion Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Nov 2019 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in USA (SC, Injection)
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 15 Apr 2017 Actelion completes a phase I trial in Healthy volunteers in USA (NCT03173625)